INS and type 1 diabetes mellitus: Use of factory-calibratedsubcutaneous glucose monitoring licensed for nonadjuvant insulin dosing hasbeen shown to attenuate hypoglycemic risk while reducing the burden ofcapillary blood glucose testing.7,8 Automated insulindelivery systems, known as artificial pancreas or closed-loop, have beenshown in free-living unsupervised home studies to improve glycemic controland to reduce the burden of hypoglycemia in people with T1D.9,10Emerging data suggest that automated insulin delivery technology may alsobenefit inpatient hyperglycemia management in those with type 2 diabetes(T2D).11,12